α-lipoic acid as a triglyceride-lowering nutraceutical

Canadian Journal of Physiology and Pharmacology

Volumn 93, Issue 12, 2015, Pages 1029-1041

  Pashaj, Anjeza ^a   Xia, Mengna ^a   Moreau, Régis ^a  

^a UNIVERSITY OF NEBRASKA LINCOLN   (United States)

Author keywords

AMPK; ChREBP; FGF21; PPAR ; SREBP1

Indexed keywords

FIBROBLAST GROWTH FACTOR 21; NUTRACEUTICAL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; THIOCTIC ACID; TRIACYLGLYCEROL;

CLINICAL TRIAL (TOPIC); DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIA; LIPOGENESIS; LIPOLYSIS; NAUSEA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SENSORIMOTOR NEUROPATHY; SKIN IRRITATION; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING; ANIMAL; BLOOD; DIETARY SUPPLEMENT; METABOLISM; OBESITY;

ANIMALS; DIETARY SUPPLEMENTS; HUMANS; OBESITY; THIOCTIC ACID; TRIGLYCERIDES;

EID: 84947596818     PISSN: 00084212     EISSN: 12057541     Source Type: Journal    
DOI: 10.1139/cjpp-2014-0480     Document Type: Review

References (209)

1. Alken, R.G., Koegst, D., and Fries, G. 2003. Treatment of lipid metabolic disorders using 5-(1,2-dithiolan-3-yl)valeric acid (a-lipoic acid) or its physiologically compatible salts. US Patent 6,518,300 B2.
2. Arner, E.S., Nordberg, J., and Holmgren, A. 1996. Efficient reduction of lipoamide and lipoic acid by mammalian thioredoxin reductase. Biochem. Biophys. Res. Commun. 225(1): 268–274. doi:10.1006/bbrc.1996.1165. PMID:8769129.
3. Artwohl, M., Muth, K., Kosulin, K., de Martin, R., Holzenbein, T., Rainer, G., et al. 2007. R-(+)-a-lipoic acid inhibits endothelial cell apoptosis and proliferation: involvement of Akt and retinoblastoma protein/E2F-1. Am. J. Physiol. Endocrinol. Metab. 293(3): E681–E689. doi:10.1152/ajpendo.00584.2006. PMID: 17566113.
4. Austin, M.A., Hokanson, J.E., and Edwards, K.L. 1998. Hypertriglyceridemia as a cardiovascular risk factor. Am. J. Cardiol. 81(4A): 7B–12B. doi:10.1016/S0002-9149(98)00031-9. PMID:9526807.
5. Badman, M.K., Pissios, P., Kennedy, A.R., Koukos, G., Flier, J.S., and Maratos-Flier, E. 2007. Hepatic fibroblast growth factor 21 is regulated by PPARa and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 5(6): 426–437. doi:10.1016/j.cmet.2007.05.002. PMID:17550778.
6. Balamurugan, K., Vaziri, N.D., and Said, H.M. 2005. Biotin uptake by human proximal tubular epithelial cells: cellular and molecular aspects. Am. J. Physiol. Renal Physiol. 288(4): F823–F831. doi:10.1152/ajprenal.00375.2004. PMID:15561972.
7. Bansal, S., Buring, J.E., Rifai, N., Mora, S., Sacks, F.M., and Ridker, P.M. 2007. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA, 298(3): 309–316. doi:10.1001/jama.298.3.309. PMID: 17635891.
8. Bays, H.E., Tighe, A.P., Sadovsky, R., and Davidson, M.H. 2008. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Rev. Cardiovasc. Ther. 6(3): 391–409. doi:10.1586/14779072.6.3.391. PMID:18327998.
9. Bennett, M.K., Lopez, J.M., Sanchez, H.B., and Osborne, T.F. 1995. Sterol regulation of fatty acid synthase promoter. Coordinate feedback regulation of two major lipid pathways. J. Biol. Chem. 270(43): 25578–25583. doi:10.1074/jbc.270.43.25578. PMID:7592729.
10. Berglund, E.D., Kang, L., Lee-Young, R.S., Hasenour, C.M., Lustig, D.G., Lynes, S.E., et al. 2010. Glucagon and lipid interactions in the regulation of hepatic AMPK signaling and expression of PPARa and FGF21 transcripts in vivo.Am.J. Physiol. Endocrinol. Metab.299(4): E607–E614. doi:10.1152/ajpendo.00263.2010. PMID:20663988.
11. Breithaupt-Grogler, K., Niebch, G., Schneider, E., Erb, K., Hermann, R., Blume, H.H., et al. 1999. Dose-proportionality of oral thioctic acid—coincidence of assessments via pooled plasma and individual data. Eur. J. Pharm. Sci. 8(1): 57–65. doi:10.1016/S0928-0987(98)00061-X. PMID:10072479.
12. Bresciani, E., Bussi, A., Bazzigaluppi, E., and Balestrieri, G. 2011. Insulin autoimmune syndrome induced by a-lipoic acid in a Caucasian woman: case report. Diabetes Care, 34(9): e146. doi:10.2337/dc11-0600. PMID:21868770.
13. Bustamante, J., Lodge, J.K., Marcocci, L., Tritschler, H.J., Packer, L., and Rihn, B.H. 1998. a-Lipoic acid in liver metabolism and disease. Free Radic. Biol. Med. 24(6): 1023–1039. doi:10.1016/S0891-5849(97)00371-7. PMID:9607614.
14. Butler, J.A., Hagen, T.M., and Moreau, R. 2009. Lipoic acid improves hypertriglyceridemia by stimulating triacylglycerol clearance and downregulating liver triacylglycerol secretion. Arch. Biochem. Biophys. 485(1): 63–71. doi:10.1016/j.abb.2009.01.024. PMID:19232511.
15. Carlson, D.A., Smith, A.R., Fischer, S.J., Young, K.L., and Packer, L. 2007. The plasma pharmacokinetics of R-(+)-lipoic acid administered as sodium R-(+)- lipoate to healthy human subjects. Altern. Med. Rev. 12(4): 343–351. PMID: 18069903.
16. Carrier, B., Wen, S., Zigouras, S., Browne, R.W., Li, Z., Patel, M.S., et al. 2014. a-Lipoic acid reduces LDL-particle number and PCSK9 concentrations in high-fat fed obese Zucker rats. PLoS One, 9(3): e90863. doi:10.1371/journal.pone.0090863. PMID:24595397.
17. Castro, M.C., Massa, M.L., Schinella, G., Gagliardino, J.J., and Francini, F. 2013. Lipoic acid prevents liver metabolic changes induced by administration of a fructose-rich diet. Biochim. Biophys. Acta, 1830(1): 2226–2232. doi:10.1016/j.bbagen.2012.10.010. PMID:23085069.
18. Chahil, T.J., and Ginsberg, H.N. 2006. Diabetic dyslipidemia. Endocrinol. Metab. Clin. North Am. 35(3): 491–510, 7-8. doi:10.1016/j.ecl.2006.06.002. PMID: 16959582.
19. Chen, W.L., Kang, C.H., Wang, S.G., and Lee, H.M. 2012. a-Lipoic acid regulates lipid metabolism through induction of sirtuin 1 (SIRT1) and activation of AMP-activated protein kinase. Diabetologia, 55(6): 1824–1835. doi:10.1007/s00125-012-2530-4. PMID:22456698.
20. Chen, Z.P., McConell, G.K., Michell, B.J., Snow, R.J., Canny, B.J., and Kemp, B.E. 2000. AMPK signaling in contracting human skeletal muscle: acetyl-CoA carboxylase and NO synthase phosphorylation. Am. J. Physiol. Endocrinol. Metab. 279(5): E1202–E1206. PMID:11052978.
21. Cho, K.J., Moini, H., Shon, H.K., Chung, A.S., and Packer, L. 2003. a-Lipoic acid decreases thiol reactivity of the insulin receptor and protein tyrosine phosphatase 1B in 3T3-L1 adipocytes. Biochem. Pharmacol. 66(5): 849–858. doi:10.1016/S0006-2952(03)00395-2. PMID:12948866.
22. Colhoun, H.M., Betteridge, D.J., Durrington, P.N., Hitman, G.A., Neil, H.A., Livingstone, S.J., et al. 2004. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet, 364(9435): 685–696. doi:10.1016/S0140-6736(04)16895-5. PMID:15325833.
23. Constantinescu, A., Pick, U., Handelman, G.J., Haramaki, N., Han, D., Podda, M., et al. 1995. Reduction and transport of lipoic acid by human erythrocytes. Biochem. Pharmacol. 50(2): 253–261. doi:10.1016/0006-2952(95)00084-D. PMID:7632170.
24. Contacos, C., Barter, P.J., and Sullivan, D.R. 1993. Effect of pravastatin and omega-3 fatty acids on plasma lipids and lipoproteins in patients with combined hyperlipidemia. Arterioscler. Thromb. 13(12): 1755–1762. doi:10.1161/01.ATV.13.12.1755. PMID:8241095.
25. Cortes, V.A., Curtis, D.E., Sukumaran, S., Shao, X., Parameswara, V., Rashid, S., et al. 2009. Molecular mechanisms of hepatic steatosis and insulin resistance in the AGPAT2-deficient mouse model of congenital generalized lipodystrophy. Cell Metab. 9(2): 165–176. doi:10.1016/j.cmet.2009.01.002. PMID:19187773.
26. Coskun, T., Bina, H.A., Schneider, M.A., Dunbar, J.D., Hu, C.C., Chen, Y., et al. 2008. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology, 149(12): 6018–6027. doi:10.1210/en.2008-0816. PMID:18687777.
27. Cremer, D.R., Rabeler, R., Roberts, A., and Lynch, B. 2006. Long-term safety of a-lipoic acid (ALA) consumption: A 2-year study. Regul. Toxicol. Pharmacol. 46(3): 193–201. doi:10.1016/j.yrtph.2006.06.003. PMID:16899332.
28. Cyphert, H.A., Alonge, K.M., Ippagunta, S.M., and Hillgartner, F.B. 2014. Glucagon stimulates hepatic FGF21 secretion through a PKA- and EPAC-dependent posttranscriptional mechanism. PLoS One, 9(4): e94996. doi:10.1371/journal.pone.0094996. PMID:24733293.
29. D’Agostino, R.B., Hamman, R.F., Karter, A.J., Mykkanen, L., Wagenknecht, L.E., and Haffner, S.M. 2004. Cardiovascular disease risk factors predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes Care, 27(9): 2234–2240. doi:10.2337/diacare.27.9.2234. PMID:15333490.
30. Dallongeville, J., Bauge, E., Tailleux, A., Peters, J.M., Gonzalez, F.J., Fruchart, J.C., and Staels, B. 2001. Peroxisome proliferator-activated receptor a is not ratelimiting for the lipoprotein-lowering action of fish oil. J. Biol. Chem. 276(7): 4634–4639. doi:10.1074/jbc.M008809200. PMID:11050100.
31. Davis, B.J., Xie, Z., Viollet, B., and Zou, M.H. 2006. Activation of the AMPactivated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. Diabetes, 55(2): 496–505. doi:10.2337/diabetes.55.02.06.db05-1064. PMID:16443786.
32. de Oliveira, A.M., Rondo, P.H., Luzia, L.A., D’Abronzo, F.H., and Illison, V.K. 2011. The effects of lipoic acid and a-tocopherol supplementation on the lipid profile and insulin sensitivity of patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Diabetes Res. Clin. Pract. 92(2): 253–260. doi:10.1016/j.diabres.2011.02.010. PMID:21371770.
33. Desai, C.S., Martin, S.S., and Blumenthal, R.S. 2014. Non-cardiovascular effects associated with statins. BMJ, 349: g3743. doi:10.1136/bmj.g3743. PMID: 25035309.
34. Diabetes Atherosclerosis Intervention Study Investigators. 2001. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet, 357(9260): 905–910. doi:10.1016/S0140-6736(00)04209-4. PMID:11289345.
35. Diesel, B., Kulhanek-Heinze, S., Holtje, M., Brandt, B., Holtje, H.D., Vollmar, A.M., and Kiemer, A.K. 2007. a-Lipoic acid as a directly binding activator of the insulin receptor: protection from hepatocyte apoptosis. Biochemistry, 46(8): 2146–2155. doi:10.1021/bi602547m. PMID:17274632.
36. Dooley, K.A., Millinder, S., and Osborne, T.F. 1998. Sterol regulation of 3-hydroxy-3-methylglutaryl-coenzyme A synthase gene through a direct interaction between sterol regulatory element binding protein and the trimeric CCAAT-binding factor/nuclear factor Y. J. Biol. Chem. 273(3): 1349–1356. doi:10.1074/jbc.273.3.1349. PMID:9430668.
37. Durrington, P.N., Bhatnagar, D., Mackness, M.I., Morgan, J., Julier, K., Khan, M.A., and France, M. 2001. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. Heart, 85(5): 544–548. doi:10.1136/heart.85.5.544. PMID:11303007.
38. Elam, M.B., Hunninghake, D.B., Davis, K.B., Garg, R., Johnson, C., Egan, D., et al. 2000. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial Disease Multiple Intervention Trial. JAMA, 284(10): 1263–1270. doi:10.1001/jama.284.10.1263. PMID:10979113.
39. Ericsson, J., Jackson, S.M., Kim, J.B., Spiegelman, B.M., and Edwards, P.A. 1997. Identification of glycerol-3-phosphate acyltransferase as an adipocyte determination and differentiation factor 1- and sterol regulatory element-binding protein-responsive gene. J. Biol. Chem. 272(11): 7298–7305. doi:10.1074/jbc.272.11.7298. PMID:9054427.
40. Finlay, L.A., Michels, A.J., Butler, J.A., Smith, E.J., Monette, J.S., Moreau, R.F., et al. 2012. R-a-lipoic acid does not reverse hepatic inflammation of aging, but lowers lipid anabolism, while accentuating circadian rhythm transcript profiles. Am. J. Physiol. Regul. Integr. Comp. Physiol. 302(5): R587–R597. doi:10.1152/ajpregu.00393.2011. PMID:22049228.
41. Foster, T.S. 2007. Efficacy and safety of a-lipoic acid supplementation in the treatment of symptomatic diabetic neuropathy. Diabetes Educ. 33(1): 111–117. doi:10.1177/0145721706297450. PMID:17272797.
42. Fujiwara, K., Okamura-Ikeda, K., and Motokawa, Y. 1990. cDNA sequence, in vitro synthesis, and intramitochondrial lipoylation of H-protein of the glycine cleavage system. J. Biol. Chem. 265(29): 17463–17467. PMID:2211640.
43. Galman, C., Lundasen, T., Kharitonenkov, A., Bina, H.A., Eriksson, M., Hafstrom, I., et al. 2008. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPAR_ activation in man. Cell Metab. 8(2): 169–174. doi:10.1016/j.cmet.2008.06.014. PMID:18680716.
44. Gerhart-Hines, Z., Dominy, J.E., Blattler, S.M., Jedrychowski, M.P., Banks, A.S., Lim, J.H., et al. 2011. The cAMP/PKA pathway rapidly activates SIRT1 to promote fatty acid oxidation independently of changes in NAD(+). Mol. Cell, 44(6): 851–863. doi:10.1016/j.molcel.2011.12.005. PMID:22195961.
45. Ghandehari, H., Le, V., Kamal-Bahl, S., Bassin, S.L., and Wong, N.D. 2009. Abdominal obesity and the spectrum of global cardiometabolic risks in US adults. Int. J. Obes. (Lond.), 33(2): 239–248. doi:10.1038/ijo.2008.252. PMID:19050677.
46. Ginsberg, H.N., Elam, M.B., Lovato, L.C., Crouse, J.R., Leiter, L.A., Linz, P., et al. 2010. Effects of combination lipid therapy in type 2 diabetes mellitus. N. Engl. J. Med. 362(17): 1563–1574. doi:10.1056/NEJMoa1001282. PMID:20228404.
47. Gleiter, C.H., Schug, B.S., Hermann, R., Elze, M., Blume, H.H., and Gundert-Remy, U. 1996. Influence of food intake on the bioavailability of thioctic acid enantiomers. Eur. J. Clin. Pharmacol. 50(6): 513–514. doi:10.1007/s002280050151. PMID:8858282.
48. Goldberg, I.J., Eckel, R.H., and McPherson, R. 2011. Triglycerides and heart disease: Still a hypothesis? Arterioscler. Thromb. Vasc. Biol. 31(8): 1716–1725. doi:10.1161/ATVBAHA.111.226100. PMID:21527746.
49. Griffin, M.J., Wong, R.H., Pandya, N., and Sul, H.S. 2007. Direct interaction between USF and SREBP-1c mediates synergistic activation of the fatty-acid synthase promoter. J. Biol. Chem. 282(8): 5453–5467. doi:10.1074/jbc.M610566200. PMID:17197698.
50. Grundy, S.M., Vega, G.L., McGovern, M.E., Tulloch, B.R., Kendall, D.M., Fitz-Patrick, D., et al. 2002. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch. Intern. Med. 162(14): 1568–1576. doi:10.1001/archinte.162.14.1568. PMID:12123399.
51. Guo, X., Kesimer, M., Tolun, G., Zheng, X., Xu, Q., Lu, J., et al. 2012. The NAD(+)- dependent protein deacetylase activity of SIRT1 is regulated by its oligomeric status. Sci. Rep. 2: 640. doi:10.1038/srep00640. PMID:22962634.
52. Hammond, L.E., Gallagher, P.A., Wang, S., Hiller, S., Kluckman, K.D., Posey-Marcos, E.L., et al. 2002. Mitochondrial glycerol-3-phosphate acyltransferase-deficient mice have reduced weight and liver triacylglycerol content and altered glycerolipid fatty acid composition. Mol. Cell. Biol. 22(23): 8204–8214. doi:10.1128/MCB.22.23.8204-8214.2002. PMID:12417724.
53. Han, D., Tritschler, H.J., and Packer, L. 1995. a-lipoic acid increases intracellular glutathione in a human T-lymphocyte Jurkat cell line. Biochem. Biophys. Res. Commun. 207(1): 258–264. doi:10.1006/bbrc.1995.1181. PMID:7857274.
54. Harchaoui, K.E., Visser, M.E., Kastelein, J.J., Stroes, E.S., and Dallinga-Thie, G.M. 2009. Triglycerides and cardiovascular risk. Curr. Cardiol. Rev. 5(3): 216–222. doi:10.2174/157340309788970315. PMID:20676280.
55. Harris, W.S., Ginsberg, H.N., Arunakul, N., Shachter, N.S., Windsor, S.L., Adams, M., et al. 1997. Safety and efficacy of Omacor in severe hypertriglyceridemia. J. Cardiovasc. Risk, 4(5–6): 385–391. doi:10.1097/00043798-199710000-00011. PMID:9865671.
56. Harrison, E.H., and McCormick, D.B. 1974. The metabolism of dl-(1,6-14C)lipoic acid in the rat. Arch. Biochem. Biophys. 160(2): 514–522. doi:10.1016/0003-9861(74)90428-7. PMID:4598618.
57. Hattori, Y., Suzuki, K., Hattori, S., and Kasai, K. 2006. Metformin inhibits cytokine-induced nuclear factor _B activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension, 47(6): 1183–1188. doi:10.1161/01.HYP.0000221429.94591.72. PMID:16636195.
58. Hawley, S.A., Boudeau, J., Reid, J.L., Mustard, K.J., Udd, L., Makela, T.P., et al. 2003. Complexes between the LKB1 tumor suppressor, STRADa/b and MO25a/b are upstream kinases in the AMP-activated protein kinase cascade. J. Biol. 2(4): 28. doi:10.1186/1475-4924-2-28. PMID:14511394.
59. Hawley, S.A., Pan, D.A., Mustard, K.J., Ross, L., Bain, J., Edelman, A.M., et al. 2005. Calmodulin-dependent protein kinase kinase-b is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab. 2(1): 9–19. doi:10.1016/j.cmet.2005.05.009. PMID:16054095.
60. Hayakawa, K., and Oizumi, J. 1988. Human serum lipoamidase. Enzyme, 40(1): 30–36. PMID:3168970.
61. Herbert, A.A., and Guest, J.R. 1975. Lipoic acid content of Escherichia coli and other microorganisms. Arch. Microbiol. 106(3): 259–266. doi:10.1007/BF00446532. PMID:814874.
62. Hermann, R., Niebch, G., Borbe, H.O., Fieger-Buschges, H., Ruus, P., Novak, H., et al. 1996. Enantioselective pharmacokinetics and bioavailability of different racemic a-lipoic acid formulations in healthy volunteers. Eur. J. Pharm. Sci. 4: 167–174. doi:10.1016/0928-0987(95)00045-3.
63. Hondares, E., Iglesias, R., Giralt, A., Gonzalez, F.J., Giralt, M., Mampel, T., and Villarroya, F. 2011. Thermogenic activation induces FGF21 expression and release in brown adipose tissue. J. Biol. Chem. 286(15): 12983–12990. doi:10.1074/jbc.M110.215889. PMID:21317437.
64. Hopkins, P.N., Heiss, G., Ellison, R.C., Province, M.A., Pankow, J.S., Eckfeldt, J.H., and Hunt, S.C. 2003. Coronary artery disease risk in familial combined hyperlipidemia and familial hypertriglyceridemia: a case-control comparison from the National Heart, Lung, and Blood Institute Family Heart Study. Circulation, 108(5): 519–523. doi:10.1161/01.CIR.0000081777.17879.85. PMID: 12847072.
65. Hou, X., Xu, S., Maitland-Toolan, K.A., Sato, K., Jiang, B., Ido, Y., et al. 2008. SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J. Biol. Chem. 283(29): 20015–20026. doi:10.1074/jbc.M802187200. PMID:18482975.
66. Hue, L., Beauloye, C., Marsin, A.S., Bertrand, L., Horman, S., and Rider, M.H. 2002. Insulin and ischemia stimulate glycolysis by acting on the same targets through different and opposing signaling pathways. J. Mol. Cell. Cardiol. 34(9): 1091–1097. doi:10.1006/jmcc.2002.2063. PMID:12392881.
67. Huong, D.T., and Ide, T. 2008. Dietary lipoic acid-dependent changes in the activity and mRNA levels of hepatic lipogenic enzymes in rats. Br. J. Nutr. 100(1): 79–87. doi:10.1017/S0007114507876227. PMID:18062843.
68. Hurley, R.L., Anderson, K.A., Franzone, J.M., Kemp, B.E., Means, A.R., and Witters, L.A. 2005. The Ca2+/calmodulin-dependent protein kinase kinases are AMP-activated protein kinase kinases. J. Biol. Chem. 280(32): 29060–29066. doi:10.1074/jbc.M503824200. PMID:15980064.
69. Huypens, P., Moens, K., Heimberg, H., Ling, Z., Pipeleers, D., and Van de Casteele, M. 2005. Adiponectin-mediated stimulation of AMPactivated protein kinase (AMPK) in pancreatic b cells. Life Sci. 77(11): 1273–1282. doi:10.1016/j.lfs.2005.03.008. PMID:15893773.
70. Igal, R.A., Wang, S., Gonzalez-Baro, M., and Coleman, R.A. 2001. Mitochondrial glycerol phosphate acyltransferase directs the incorporation of exogenous fatty acids into triacylglycerol. J. Biol. Chem. 276(45): 42205–42212. doi:10.1074/jbc.M103386200. PMID:11546763.
71. Inagaki, T., Dutchak, P., Zhao, G., Ding, X., Gautron, L., Parameswara, V., et al. 2007. Endocrine regulation of the fasting response by PPARa-mediated induction of fibroblast growth factor 21. Cell Metab. 5(6): 415–425. doi:10.1016/.cmet.2007.05.003. PMID:17550777.
72. Inoki, K., Ouyang, H., Zhu, T., Lindvall, C., Wang, Y., Zhang, X., et al. 2006. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell, 126(5): 955–968. doi:10.1016/j.cell.2006.06.055. PMID:16959574.
73. Irrcher, I., Walkinshaw, D.R., Sheehan, T.E., and Hood, D.A. 2007. Thyroid hormone (T3) rapidly activates p38 and AMPK in skeletal muscle in vivo. J. Appl. Physiol. 104(1): 178–185. doi:10.1152/japplphysiol.00643.2007. PMID:17962579.
74. Ito, M.K. 2003. Advances in the understanding and management of dyslipidemia: using niacin-based therapies. Am. J. Health Syst. Pharm. 60(13): S15–S21; quiz S25. 12901026.
75. Izumiya, Y., Bina, H.A., Ouchi, N., Akasaki, Y., Kharitonenkov, A., and Walsh, K. 2008. FGF21 is an Akt-regulated myokine. FEBS Lett. 582(27): 3805–3810. doi: 10.1016/j.febslet.2008.10.021. PMID:18948104.
76. Jackson, S.M., Ericsson, J., Mantovani, R., and Edwards, P.A. 1998. Synergistic activation of transcription by nuclear factor Y and sterol regulatory element binding protein. J. Lipid Res. 39(4): 767–776. PMID:9555942.
77. Jacobson, T.A., and Zimmerman, F.H. 2006. Fibrates in combination with statins in the management of dyslipidemia. J. Clin. Hypertens. (Greenwich), 8(1): 35–41;quiz 42–33. doi:10.1111/j.1524-6175.2005.05278.x. PMID:16407687.
78. Jeppesen, J., Hein, H.O., Suadicani, P., and Gyntelberg, F. 1998. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation, 97(11): 1029–1036. doi:10.1161/01.CIR.97.11.1029. PMID:9531248.
79. Jiang, G., and Zhang, B.B. 2003. Glucagon and regulation of glucose metabolism. Am. J. Physiol. Endocrinol. Metab. 284(4): E671–E678. doi:10.1152/ajpendo.00492.2002. PMID:12626323.
80. Junter, G.A., Selegny, E., and Lemeland, J.F. 1980. [An electrochemical evidence that some hormones influence the transmembrane transport of lipoic acid by Escherichio coli K 12 (author’s transl)]. Pathol. Biol. (Paris), 28(7): 435–439. PMID:6775269.
81. Kataoka, H., Hirabayashi, N., and Makita, M. 1997. Analysis of lipoic acid by gas chromatography with flame photometric detection. Methods Enzymol. 279: 166–176. doi:10.1016/S0076-6879(97)79020-7. PMID:9211268.
82. Ke, B. 1957. The polarographic behavior of a-lipoic acid. Biochim. Biophys. Acta, 25(3): 650–651. doi:10.1016/0006-3002(57)90544-9. PMID:13479444.
83. Keech, A., Simes, R.J., Barter, P., Best, J., Scott, R., Taskinen, M.R., et al. 2005. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet, 366(9500): 1849–1861. doi:10.1016/S0140-6736(05)67667-2. PMID:16310551.
84. Kemp, B.E., Mitchelhill, K.I., Stapleton, D., Michell, B.J., Chen, Z.P., and Witters, L.A. 1999. Dealing with energy demand: the AMP-activated protein kinase. Trends Biochem. Sci. 24(1): 22–25. doi:10.1016/S0968-0004(98)01340-1. PMID:10087918.
85. Khabbazi, T., Mahdavi, R., Safa, J., and Pour-Abdollahi, P. 2012. Effects of a-lipoic acid supplementation on inflammation, oxidative stress, and serum lipid profile levels in patients with end-stage renal disease on hemodialysis. J. Ren. Nutr. 22(2): 244–250. doi:10.1053/j.jrn.2011.06.005. PMID:21908204.
86. Kharitonenkov, A., Shiyanova, T.L., Koester, A., Ford, A.M., Micanovic, R., Galbreath, E.J., et al. 2005. FGF-21 as a novel metabolic regulator. J. Clin. Invest. 115(6): 1627–1635. doi:10.1172/JCI23606. PMID:15902306.
87. Kharitonenkov, A., Dunbar, J.D., Bina, H.A., Bright, S., Moyers, J.S., Zhang, C., et al. 2008. FGF-21/FGF-21 receptor interaction and activation is determined by bKlotho. J. Cell. Physiol. 215(1): 1–7. doi:10.1002/jcp.21357. PMID:18064602.
88. Kim, E., Park, D.W., Choi, S.H., Kim, J.J., and Cho, H.S. 2008. A preliminary investigation of _-lipoic acid treatment of antipsychotic drug-induced weight gain in patients with schizophrenia. J. Clin. Psychopharmacol. 28(2): 138–146. doi:10.1097/JCP.0b013e31816777f7. PMID:18344723.
89. Kim, M.S., Park, J.Y., Namkoong, C., Jang, P.G., Ryu, J.W., Song, H.S., et al. 2004. Anti-obesity effects of a-lipoic acid mediated by suppression of hypothalamic AMP-activated protein kinase. Nat. Med. 10(7): 727–733. doi:10.1038/nm1061. PMID:15195087.
90. Kim, Y., and Oliver, D.J. 1990. Molecular cloning, transcriptional characterization, and sequencing of cDNA encoding the H-protein of the mitochondrial glycine decarboxylase complex in peas. J. Biol. Chem. 265(2): 848–853. PMID: 1688555.
91. Koh, E.H., Lee, W.J., Lee, S.A., Kim, E.H., Cho, E.H., Jeong, E., et al. 2011. Effects of a-lipoic Acid on body weight in obese subjects. Am. J. Med. 124(1): 85.e1–85.e8. doi:10.1016/j.amjmed.2010.08.005. PMID:21187189.
92. Kurth-Kraczek, E.J., Hirshman, M.F., Goodyear, L.J., and Winder, W.W. 1999. 5= AMP-activated protein kinase activation causes GLUT4 translocation in skeletal muscle. Diabetes, 48(8): 1667–1671. doi:10.2337/diabetes.48.8.1667. PMID: 10426389.
93. Lazennec, G., Canaple, L., Saugy, D., and Wahli, W. 2000. Activation of peroxisome proliferator-activated receptors (PPARs) by their ligands and protein kinase A activators. Mol. Endocrinol. 14(12): 1962–1975. doi:10.1210/mend.14.12.0575. PMID:11117527.
94. Lee, W.J., Lee, I.K., Kim, H.S., Kim, Y.M., Koh, E.H., Won, J.C., et al. 2005a. a-Lipoic acid prevents endothelial dysfunction in obese rats via activation of AMPactivated protein kinase. Arterioscler. Thromb. Vasc. Biol. 25(12): 2488–2494. doi:10.1161/01.ATV.0000190667.33224.4c. PMID:16224049.
95. Lee, W.J., Song, K.H., Koh, E.H., Won, J.C., Kim, H.S., Park, H.S., et al. 2005b. a-Lipoic acid increases insulin sensitivity by activating AMPK in skeletal muscle. Biochem. Biophys. Res. Commun. 332(3): 885–891. doi:10.1016/j.bbrc.2005.05.035. PMID:15913551.
96. Lee, Y., Naseem, R.H., Park, B.H., Garry, D.J., Richardson, J.A., Schaffer, J.E., and Unger, R.H. 2006. a-Lipoic acid prevents lipotoxic cardiomyopathy in acyl CoA-synthase transgenic mice. Biochem. Biophys. Res. Commun. 344(1): 446–452. doi:10.1016/j.bbrc.2006.03.062. PMID:16603124.
97. Lewin, T.M., Granger, D.A., Kim, J.H., and Coleman, R.A. 2001. Regulation of mitochondrial sn-glycerol-3-phosphate acyltransferase activity: response to feeding status is unique in various rat tissues and is discordant with protein expression. Arch. Biochem. Biophys. 396(1): 119–127. doi:10.1006/abbi.2001.2604. PMID:11716470.
98. Li, J., Jiang, P., Robinson, M., Lawrence, T.S., and Sun, Y. 2003. AMPK-b1 subunit is a p53-independent stress responsive protein that inhibits tumor cell growth upon forced expression. Carcinogenesis, 24(5): 827–834. doi:10.1093/carcin/bgg032. PMID:12771025.
99. Li, L., Wu, L., Wang, C., Liu, L., and Zhao, Y. 2007. Adiponectin modulates carnitine palmitoyltransferase-1 through AMPK signaling cascade in rat cardiomyocytes. Regul. Pept. 139(1–3): 72–79. doi:10.1016/j.regpep.2006.10.007. PMID: 17109977.
100. Lodge, J.K., Youn, H.D., Handelman, G.J., Konishi, T., Matsugo, S., Mathur, V.V., and Packer, L. 1997. Natural sources of lipoic acid: determination of lipoyllysine released from protease-digested tissues by high performance liquid chromatography incorporating electrochemical detection. J. Appl. Nutr. 49: 3–11.
101. Lundasen, T., Hunt, M.C., Nilsson, L.M., Sanyal, S., Angelin, B., Alexson, S.E., and Rudling, M. 2007. PPAR_ is a key regulator of hepatic FGF21. Biochem. Biophys. Res. Commun. 360(2): 437–440. doi:10.1016/j.bbrc.2007.06.068. PMID: 17601491.
102. Macherel, D., Lebrun, M., Gagnon, J., Neuburger, M., and Douce, R. 1990. cDNA cloning, primary structure and gene expression for H-protein, a component of the glycine-cleavage system (glycine decarboxylase) of pea (Pisum sativum) leaf mitochondria. Biochem. J. 268(3): 783–789. PMID:2363710.
103. Mahley, R.W., Innerarity, T.L., Rall, S.C., Jr., and Weisgraber, K.H. 1985. Lipoproteins of special significance in atherosclerosis. Insights provided by studies of type III hyperlipoproteinemia. Ann. N.Y. Acad. Sci. 454: 209–221. doi:10.1111/j.1749-6632.1985.tb11860.x. PMID:3000263.
104. Mamo, J.C., Proctor, S.D., and Smith, D. 1998. Retention of chylomicron remnants by arterial tissue; importance of an efficient clearance mechanism from plasma. Atherosclerosis, 141(1): S63–S69. doi:10.1016/S0021-9150(98)00220-2. PMID:9888645.
105. Manning, P.J., Sutherland, W.H., Williams, S.M., Walker, R.J., Berry, E.A., De Jong, S.A., and Ryalls, A.R. 2013. The effect of lipoic acid and vitamin E therapies in individuals with the metabolic syndrome. Nutr. Metab. Cardiovasc. Dis. 23(6): 543–549. doi:10.1016/j.numecd.2011.11.006. PMID:22402059.
106. Marsin, A.S., Bertrand, L., Rider, M.H., Deprez, J., Beauloye, C., Vincent, M.F., et al. 2000. Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia. Curr. Biol. 10(20): 1247–1255. doi:10.1016/S0960-9822(00)00742-9. PMID:11069105.
107. Masharani, U., Gjerde, C., Evans, J.L., Youngren, J.F., and Goldfine, I.D. 2010. Effects of controlled-release a lipoic acid in lean, nondiabetic patients with polycystic ovary syndrome. J. Diabetes Sci. Technol. 4(2): 359–364. doi:10.1177/193229681000400218. PMID:20307398.
108. Matuda, S., and Saheki, T. 1982. Intracellular distribution and biosynthesis of lipoamide dehydrogenase in rat liver. J. Biochem. 91(2): 553–561. PMID: 6896050.
109. McIlduff, C.E., and Rutkove, S.B. 2011. Critical appraisal of the use of _ lipoic acid (thioctic acid) in the treatment of symptomatic diabetic polyneuropathy. Ther. Clin. Risk Manag. 7: 377–385. doi:10.2147/TCRM.S11325. PMID:21941444.
110. McKenney, J. 2004. New perspectives on the use of niacin in the treatment of lipid disorders. Arch. Intern. Med. 164(7): 697–705. doi:10.1001/archinte.164.7.697. PMID:15078639.
111. McNeilly, A.M., Davison, G.W., Murphy, M.H., Nadeem, N., Trinick, T., Duly, E., et al. 2011. Effect of a-lipoic acid and exercise training on cardiovascular disease risk in obesity with impaired glucose tolerance. Lipids Health Dis. 10: 217. doi:10.1186/1476-511X-10-217. PMID:22107734.
112. Merrill, G.F., Kurth, E.J., Hardie, D.G., and Winder, W.W. 1997. AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle. Am. J. Physiol. 273(6): E1107–E1112. PMID:9435525.
113. Mignini, F., Streccioni, V., Tomassoni, D., Traini, E., and Amenta, F. 2007. Comparative crossover, randomized, open-label bioequivalence study on the bioequivalence of two formulations of thioctic acid in healthy volunteers. Clin. Exp. Hypertens. 29(8): 575–586. doi:10.1080/10641960701744111. PMID: 18058482.
114. Miller, M. 2003. Niacin as a component of combination therapy for dyslipidemia. Mayo Clin. Proc. 78(6): 735–742. doi:10.4065/78.6.735. PMID:12934785.
115. Miller, M., Cannon, C.P., Murphy, S.A., Qin, J., Ray, K.K., and Braunwald, E. 2008. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J. Am. Coll. Cardiol. 51(7): 724–730. doi:10.1016/j.jacc.2007.10.038. PMID:18279736.
116. Min, A.K., Kim, M.K., Seo, H.Y., Kim, H.S., Jang, B.K., Hwang, J.S., et al. 2010. a-Lipoic acid inhibits hepatic PAI-1 expression and fibrosis by inhibiting the TGF-b signaling pathway. Biochem. Biophys. Res. Commun. 393(3): 536–541. doi:10.1016/j.bbrc.2010.02.050. PMID:20153726.
117. Minokoshi, Y., Kim, Y.B., Peroni, O.D., Fryer, L.G., Muller, C., Carling, D., and Kahn, B.B. 2002. Leptin stimulates fatty-acid oxidation by activating AMPactivated protein kinase. Nature, 415(6869): 339–343. doi:10.1038/415339a. PMID:11797013.
118. Muise, E.S., Azzolina, B., Kuo, D.W., El-Sherbeini, M., Tan, Y., Yuan, X., et al. 2008. Adipose fibroblast growth factor 21 is up-regulated by peroxisome proliferator-activated receptor _ and altered metabolic states. Mol. Pharmacol. 74(2): 403–412. doi:10.1124/mol.108.044826. PMID:18467542.
119. Muoio, D.M., Seefeld, K., Witters, L.A., and Coleman, R.A. 1999. AMP-activated kinase reciprocally regulates triacylglycerol synthesis and fatty acid oxidation in liver and muscle: evidence that sn-glycerol-3-phosphate acyltransferase is a novel target. Biochem. J. 338(3): 783–791. doi:10.1042/0264-6021: 3380783. PMID:10051453.
120. NCEP. 2001. Executive summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA, 285(19): 2486–2497. doi:10.1001/jama.285.19.2486. PMID:11368702.
121. NCEP. 2002. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation, 106(25): 3143–3421. PMID:12485966.
122. Nesto, R.W. 2005. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. Am. J. Cardiovasc. Drugs, 5(6): 379–387. doi:10.2165/00129784-200505060-00005. PMID:16259526.
123. Nishimura, T., Nakatake, Y., Konishi, M., and Itoh, N. 2000. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim. Biophys. Acta, 1492(1): 203–206. doi:10.1016/S0167-4781(00)00067-1. PMID:10858549.
124. Nordestgaard, B.G., Benn, M., Schnohr, P., and Tybjaerg-Hansen, A. 2007. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA, 298(3): 299–308. doi:10.1001/jama.298.3.299. PMID:17635890.
125. O’Callaghan, B.L., Koo, S.H., Wu, Y., Freake, H.C., and Towle, H.C. 2001. Glucose regulation of the acetyl-CoA carboxylase promoter PI in rat hepatocytes. J. Biol. Chem. 276(19): 16033–16039. doi:10.1074/jbc.M101557200. PMID: 11340083.
126. Ogawa, Y., Kurosu, H., Yamamoto, M., Nandi, A., Rosenblatt, K.P., Goetz, R., et al. 2007. bKlotho is required for metabolic activity of fibroblast growth factor 21. Proc. Natl. Acad. Sci. U.S.A. 104(18): 7432–7437. doi:10.1073/pnas.0701600104. PMID:17452648.
127. Ogborne, R.M., Rushworth, S.A., and O’Connell, M.A. 2005. a-Lipoic acid-induced heme oxygenase-1 expression is mediated by nuclear factor erythroid 2-related factor 2 and p38 mitogen-activated protein kinase in human monocytic cells. Arterioscler. Thromb. Vasc. Biol. 25(10): 2100–2105. doi:10.1161/01.ATV.0000183745.37161.6e. PMID:16123320.
128. Packer, L., Witt, E.H., and Tritschler, H.J. 1995. a-Lipoic acid as a biological antioxidant. Free Radic. Biol. Med. 19(2): 227–250. doi:10.1016/0891-5849(95)00017-R. PMID:7649494.
129. Park, K.G., Min, A.K., Koh, E.H., Kim, H.S., Kim, M.O., Park, H.S., et al. 2008. a-Lipoic acid decreases hepatic lipogenesis through adenosine monophosphate-activated protein kinase (AMPK)-dependent and AMPKindependent pathways. Hepatology, 48(5): 1477–1486. doi:10.1002/hep.22496. PMID:18972440.
130. Park, H., Kaushik, V.K., Constant, S., Prentki, M., Przybytkowski, E., Ruderman, N.B., and Saha, A.K. 2002a. Coordinate regulation of malonyl-CoA decarboxylase, sn-glycerol-3-phosphate acyltransferase, and acetyl-CoA carboxylase by AMP-activated protein kinase in rat tissues in response to exercise. J. Biol. Chem. 277(36): 32571–32577. doi:10.1074/jbc.M201692200. PMID: 12065578.
131. Park, S.H., Paulsen, S.R., Gammon, S.R., Mustard, K.J., Hardie, D.G., and Winder, W.W. 2002b. Effects of thyroid state on AMP-activated protein kinase and acetyl-CoA carboxylase expression in muscle. J. Appl. Physiol. 93(6): 2081–2088. doi:10.1152/japplphysiol.00504.2002. PMID:12433937.
132. Park, Z.H., Juska, A., Dyakov, D., and Patel, R.V. 2014. Statin-associated incident diabetes: a literature review. Consult. Pharm. 29(5): 317–334. doi:10.4140/TCP.n.2014.317. PMID:24849689.
133. Pashaj, A., Yi, X., Xia, M., Canny, S., Riethoven, J.J., and Moreau, R. 2013. Characterization of genome-wide transcriptional changes in liver and adipose tissues of ZDF (fa/fa) rats fed R-a-lipoic acid by next-generation sequencing. Physiol. Genomics, 45(23): 1136–1143. doi:10.1152/physiolgenomics.00138.2013. PMID:24104204.
134. Peinado, J., Sies, H., and Akerboom, T.P. 1989. Hepatic lipoate uptake. Arch. Biochem. Biophys. 273(2): 389–395. doi:10.1016/0003-9861(89)90497-9. PMID: 2505669.
135. Pejic, R.N., and Lee, D.T. 2006. Hypertriglyceridemia. J. Am. Board Fam. Med. 19(3): 310–316. doi:10.3122/jabfm.19.3.310. PMID:16672684.
136. Perham, R.N. 1991. Domains, motifs, and linkers in 2-oxo acid dehydrogenase multienzyme complexes: a paradigm in the design of a multifunctional protein. Biochemistry, 30(35): 8501–8512. doi:10.1021/bi00099a001. PMID: 1888719.
137. Petersen Shay, K., Moreau, R.F., Smith, E.J., and Hagen, T.M. 2008. Is a-lipoic acid a scavenger of reactive oxygen species in vivo? Evidence for its initiation of stress signaling pathways that promote endogenous antioxidant capacity. IUBMB Life, 60(6): 362–367. doi:10.1002/iub.40. PMID:18409172.
138. Pick, U., Haramaki, N., Constantinescu, A., Handelman, G.J., Tritschler, H.J., and Packer, L. 1995. Glutathione reductase and lipoamide dehydrogenase have opposite stereospecificities for a-lipoic acid enantiomers. Biochem. Biophys. Res. Commun. 206(2): 724–730. doi:10.1006/bbrc.1995.1102. PMID:7826393.
139. Pilon, G., Dallaire, P., and Marette, A. 2004. Inhibition of inducible nitric-oxide synthase by activators of AMP-activated protein kinase: a new mechanism of action of insulin-sensitizing drugs. J. Biol. Chem. 279(20): 20767–20774. doi: 10.1074/jbc.M401390200. PMID:14985344.
140. Pownall, H.J., Brauchi, D., Kilinc, C., Osmundsen, K., Pao, Q., Payton-Ross, C., et al. 1999. Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis, 143(2): 285–297. doi:10.1016/S0021-9150(98)00301-3. PMID:10217357.
141. Prasad, P.D., Wang, H., Kekuda, R., Fujita, T., Fei, Y.J., Devoe, L.D., et al. 1998. Cloning and functional expression of a cDNA encoding a mammalian sodium-dependent vitamin transporter mediating the uptake of pantothenate, biotin, and lipoate. J. Biol. Chem. 273(13): 7501–7506. doi:10.1074/jbc.273.13.7501. PMID:9516450.
142. Preiss, D., Seshasai, S.R., Welsh, P., Murphy, S.A., Ho, J.E., Waters, D.D., et al. 2011. Risk of incident diabetes with intensive-dose compared with moderatedose statin therapy: a meta-analysis. JAMA, 305(24): 2556–2564. doi:10.1001/jama.2011.860. PMID:21693744.
143. Price, N.L., Gomes, A.P., Ling, A.J., Duarte, F.V., Martin-Montalvo, A., North, B.J., et al. 2012. SIRT1 is required for AMPK activation and the beneficial effects of resveratrolonmitochondrial function. Cell Metab. 15(5): 675–690. doi:10.1016/j.cmet.2012.04.003. PMID:22560220.
144. Reed, B.D., Charos, A.E., Szekely, A.M., Weissman, S.M., and Snyder, M. 2008. Genome-wide occupancy of SREBP1 and its partners NFY and SP1 reveals novel functional roles and combinatorial regulation of distinct classes of genes. PLoS Genet. 4(7): e1000133. doi:10.1371/journal.pgen.1000133. PMID: 18654640.
145. Reed, L.J., and Hackert, M.L. 1990. Structure–function relationships in dihydrolipoamide acyltransferases. J. Biol. Chem. 265(16): 8971–8974. PMID:2188967.
146. Resnick, H.E., Foster, G.L., Bardsley, J., and Ratner, R.E. 2006. Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey. Diabetes Care, 29(3): 531–537. doi:10.2337/diacare.29.03.06.dc05-1254. PMID:16505501.
147. Revollo, J.R., Grimm, A.A., and Imai, S. 2004. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J. Biol. Chem. 279(49): 50754–50763. doi:10.1074/jbc.M408388200. PMID:15381699.
148. Ridker, P.M., Danielson, E., Fonseca, F.A., Genest, J., Gotto, A.M., Kastelein, J.J., et al. 2008. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359(21): 2195–2207. doi:10.1056/NEJMoa0807646. PMID:18997196.
149. Rubins, H.B., Robins, S.J., Collins, D., Fye, C.L., Anderson, J.W., Elam, M.B., et al. 1999. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med. 341(6): 410–418. doi:10.1056/nejm199908053410604. PMID: 10438259.
150. Rufo, C., Teran-Garcia, M., Nakamura, M.T., Koo, S.H., Towle, H.C., and Clarke, S.D. 2001. Involvement of a unique carbohydrate-responsive factor in the glucose regulation of rat liver fatty-acid synthase gene transcription. J. Biol. Chem. 276(24): 21969–21975. doi:10.1074/jbc.M100461200. PMID: 11279238.
151. Ruhnau, K.J., Meissner, H.P., Finn, J.R., Reljanovic, M., Lobisch, M., Schutte, K., et al. 1999. Effects of 3-week oral treatment with the antioxidant thioctic acid (a-lipoic acid) in symptomatic diabetic polyneuropathy. Diabet. Med. 16(12): 1040–1043. doi:10.1046/j.1464-5491.1999.00190.x. PMID:10656234.
152. Rutledge, J.C., Mullick, A.E., Gardner, G., and Goldberg, I.J. 2000. Direct visualization of lipid deposition and reverse lipid transport in a perfused artery: roles of VLDL and HDL. Circ. Res. 86(7): 768–773. doi:10.1161/01.RES.86.7.768. PMID:10764410.
153. Salinthone, S., Schillace, R.V., Marracci, G.H., Bourdette, D.N., and Carr, D.W. 2008. Lipoic acid stimulates cAMP production via the EP2 and EP4 prostanoid receptors and inhibits IFN g synthesis and cellular cytotoxicity in NK cells. J. Neuroimmunol. 199(1–2): 46–55. doi:10.1016/j.jneuroim.2008.05.003. PMID: 18562016.
154. Salinthone, S., Schillace, R.V., Tsang, C., Regan, J.W., Bourdette, D.N., and Carr, D.W. 2011. Lipoic acid stimulates cAMP production via G proteincoupled receptor-dependent and -independent mechanisms. J. Nutr. Biochem. 22(7): 681–690. doi:10.1016/j.jnutbio.2010.05.008. PMID:21036588.
155. Samson, S.L., and Wong, N.C. 2002. Role of Sp1 in insulin regulation of gene expression. J. Mol. Endocrinol. 29(3): 265–279. doi:10.1677/jme.0.0290265. PMID:12459029.
156. Sanchez, H.B., Yieh, L., and Osborne, T.F. 1995. Cooperation by sterol regulatory element-binding protein and Sp1 in sterol regulation of low density lipoprotein receptor gene. J. Biol. Chem. 270(3): 1161–1169. doi:10.1074/jbc.270.3.1161. PMID:7836375.
157. Satoh, S., Masatoshi, S., Shou, Z., Yamamoto, T., Ishigure, T., Semii, A., et al. 2007. Identification of cis-regulatory elements and trans-acting proteins of the rat carbohydrate response element binding protein gene. Arch. Biochem. Biophys. 461(1): 113–122. doi:10.1016/j.abb.2007.02.028. PMID:17418800.
158. Schillace, R.V., Pisenti, N., Pattamanuch, N., Galligan, S., Marracci, G.H., Bourdette, D.N., and Carr, D.W. 2007. Lipoic acid stimulates cAMP production in T lymphocytes and NK cells. Biochem. Biophys. Res. Commun. 354(1): 259–264. doi:10.1016/j.bbrc.2006.12.195. PMID:17210133.
159. Segermann, J., Hotze, A., Ulrich, H., and Rao, G.S. 1991. Effect of a-lipoic acid on the peripheral conversion of thyroxine to triiodothyronine and on serum lipid-, protein- and glucose levels. Arzneimittelforschung, 41(12): 1294–1298. PMID:1815532.
160. Shaw, R.J., Kosmatka, M., Bardeesy, N., Hurley, R.L., Witters, L.A., DePinho, R.A., and Cantley, L.C. 2004. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc. Natl. Acad. Sci. U.S.A. 101(10): 3329–3335. doi:10.1073/pnas.0308061100. PMID:14985505.
161. Shay, K.P., Moreau, R.F., Smith, E.J., Smith, A.R., and Hagen, T.M. 2009. a-Lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochim. Biophys. Acta, 1790(10): 1149–1160. doi:10.1016/j.bbagen.2009.07.026. PMID:19664690.
162. Shen, Q.W., Jones, C.S., Kalchayanand, N., Zhu, M.J., and Du, M. 2005. Effect of dietary a-lipoic acid on growth, body composition, muscle pH, and AMPactivated protein kinase phosphorylation in mice. J. Anim. Sci. 83(11): 2611–2617. PMID:16230659.
163. 2+/calmodulindependent protein kinase kinase is involved in AMP-activated protein kinase activation by a-lipoic acid in C2C12 myotubes. Am. J. Physiol. Cell Physiol. 293(4): C1395–C1403. PMID:17687000.
164. Shepherd, J., Betteridge, J., and Van Gaal, L. 2005. Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel. Curr. Med. Res. Opin. 21(5): 665–682. doi:10.1185/030079905X43677. PMID:15969866.
165. Spence, J.T., and McCormick, D.B. 1976. Lipoic acid metabolism in the rat. Arch. Biochem. Biophys. 174(1): 13–19. doi:10.1016/0003-9861(76)90318-0. PMID: 779655.
166. Sprecher, D.L., Pearce, G.L., Park, E.M., Pashkow, F.J., and Hoogwerf, B.J. 2000. Preoperative triglycerides predict post-coronary artery bypass graft survival in diabetic patients: a sex analysis. Diabetes Care, 23(11): 1648–1653. doi:10.2337/diacare.23.11.1648. PMID:11092287.
167. Stalenhoef, A.F., de Graaf, J., Wittekoek, M.E., Bredie, S.J., Demacker, P.N., and Kastelein, J.J. 2000. The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia. Atherosclerosis, 153(1): 129–138. doi:10.1016/S0021-9150(00)00381-6. PMID:11058707.
168. Subramanian, S., and Chait, A. 2012. Hypertriglyceridemia secondary to obesity and diabetes. Biochim. Biophys. Acta, 1821(5): 819–825. doi:10.1016/j.bbalip.2011.10.003. PMID:22005032.
169. Sun, Y.D., Dong, Y.D., Fan, R., Zhai, L.L., Bai, Y.L., and Jia, L.H. 2012. Effect of (R)-a-lipoic acid supplementation on serum lipids and antioxidative ability in patients with age-related macular degeneration. Ann. Nutr. Metab. 60(4): 293–297. doi:10.1159/000338444. PMID:22678104.
170. Suzuki, M., Uehara, Y., Motomura-Matsuzaka, K., Oki, J., Koyama, Y., Kimura, M., et al. 2008. bKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Mol. Endocrinol. 22(4): 1006–1014. doi:10.1210/me.2007-0313. PMID:18187602.
171. Suzuki, Y.J., Tsuchiya, M., and Packer, L. 1991. Thioctic acid and dihydrolipoic acid are novel antioxidants which interact with reactive oxygen species. Free Radic. Res. Commun. 15(5): 255–263. doi:10.3109/10715769109105221. PMID: 1666623.
172. Suzuki, Y.J., Tsuchiya, M., and Packer, L. 1993. Antioxidant activities of dihydrolipoic acid and its structural homologues. Free Radic. Res. Commun. 18(2): 115–122. doi:10.3109/10715769309147348. PMID:8386684.
173. Takaishi, N., Yoshida, K., Satsu, H., and Shimizu, M. 2007. Transepithelial transport of a-lipoic acid across human intestinal Caco-2 cell monolayers. J. Agric. Food Chem. 55(13): 5253–5259. doi:10.1021/jf063624i. PMID:17536819.
174. Takeuchi, Y., Miyamoto, T., Kakizawa, T., Shigematsu, S., and Hashizume, K. 2007. Insulin Autoimmune Syndrome possibly caused by a lipoic acid. Intern. Med. 46(5): 237–239. doi:10.2169/internalmedicine.46.1893. PMID:17329919.
175. Teichert, J., and Preiss, R. 1992. HPLC-methods for determination of lipoic acid and its reduced form in human plasma. Int. J. Clin. Pharmacol. Ther. Toxicol. 30(11): 511–512. PMID:1490813.
176. Teichert, J., Tuemmers, T., Achenbach, H., Preiss, C., Hermann, R., Ruus, P., and Preiss, R. 2005. Pharmacokinetics of a-lipoic acid in subjects with severe kidney damage and end-stage renal disease. J. Clin. Pharmacol. 45(3): 313–328. doi:10.1177/0091270004270792. PMID:15703366.
177. Thirunavukkarasu, V., Anitha Nandhini, A.T., and Anuradha, C.V. 2004. Effect of a-lipoic acid on lipid profile in rats fed a high-fructose diet. Exp. Diabesity Res. 5(3): 195–200. doi:10.1080/15438600490486778. PMID:15512787.
178. Timmers, S., de Vogel-van den Bosch, J., Towler, M.C., Schaart, G., Moonen-Kornips, E., Mensink, R.P., et al. 2010. Prevention of high-fat dietinduced muscular lipid accumulation in rats by a lipoic acid is not mediated by AMPK activation. J. Lipid Res. 51(2): 352–359. doi:10.1194/jlr.M000992. PMID:19690335.
179. Tong, X., Moreau, R., and Su, Q. 2014. Activation of hepatic CREBH-Insig-2a signaling in the triglyceride-lowering mechanism of R-a-lipoic acid. Arterioscler. Thromb. Vasc. Biol. 34: A440.
180. Uebanso, T., Taketani, Y., Fukaya, M., Sato, K., Takei, Y., Sato, T., et al. 2009. Hypocaloric high-protein diet improves fatty liver and hypertriglyceridemia in sucrose-fed obese rats via two pathways. Am. J. Physiol. Endocrinol. Metab. 297(1): E76–E84. doi:10.1152/ajpendo.00014.2009. PMID:19435858.
181. Uotani, S., Abe, T., and Yamaguchi, Y. 2006. Leptin activates AMP-activated protein kinase in hepatic cells via a JAK2-dependent pathway. Biochem. Biophys. Res. Commun. 351(1): 171–175. doi:10.1016/j.bbrc.2006.10.015. PMID:17054914.
182. Vakkilainen, J., Steiner, G., Ansquer, J.C., Perttunen-Nio, H., and Taskinen, M.R. 2002. Fenofibrate lowers plasma triglycerides and increases LDL particle diameter in subjects with type 2 diabetes. Diabetes Care, 25(3): 627–628. doi:10.2337/diacare.25.3.627. PMID:11874962.
183. Valdecantos, M.P., Perez-Matute, P., Gonzalez-Muniesa, P., Prieto-Hontoria, P.L., Moreno-Aliaga, M.J., and Martinez, J.A. 2012. Lipoic acid administration prevents nonalcoholic steatosis linked to long-term high-fat feeding by modulating mitochondrial function. J. Nutr. Biochem. 23(12): 1676–1684. doi:10.1016/j.jnutbio.2011.11.011. PMID:22464149.
184. Westphal, S., Orth, M., Ambrosch, A., Osmundsen, K., and Luley, C. 2000. Postprandial chylomicrons and VLDLs in severe hypertriacylglycerolemia are lowered more effectively than are chylomicron remnants after treatment with n-3 fatty acids. Am. J. Clin. Nutr. 71(4): 914–920. PMID:10731497.
185. Wong, R.H., and Sul, H.S. 2010. Insulin signaling in fatty acid and fat synthesis: a transcriptional perspective. Curr. Opin. Pharmacol. 10(6): 684–691. doi:10.1016/j.coph.2010.08.004. PMID:20817607.
186. Woods, A., Johnstone, S.R., Dickerson, K., Leiper, F.C., Fryer, L.G., Neumann, D., et al. 2003. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr. Biol. 13(22): 2004–2008. doi:10.1016/j.cub.2003.10.031. PMID: 14614828.
187. 2+/calmodulin-dependent protein kinase kinase-b acts upstream of AMP-activated protein kinase in mammalian cells. Cell Metab. 2(1): 21–33. doi:10.1016/j.cmet.2005.06.005. PMID:16054096.
188. Xi, X., Han, J., and Zhang, J.Z. 2001. Stimulation of glucose transport by AMPactivated protein kinase via activation of p38 mitogen-activated protein kinase. J. Biol. Chem. 276(44): 41029–41034. doi:10.1074/jbc.M102824200. PMID: 11546797.
189. Xiang, G., Pu, J., Yue, L., Hou, J., and Sun, H. 2011. a-Lipoic acid can improve endothelial dysfunction in subjects with impaired fasting glucose. Metabolism, 60(4): 480–485. doi:10.1016/j.metabol.2010.04.011. PMID:21255807.
190. Xiao, C., Giacca, A., and Lewis, G.F. 2011. Short-term oral a-lipoic acid does not prevent lipid-induced dysregulation of glucose homeostasis in obese and overweight nondiabetic men. Am. J. Physiol. Endocrinol. Metab. 301(4): E736–E741. doi:10.1152/ajpendo.00183.2011. PMID:21750266.
191. Xu, J., Lloyd, D.J., Hale, C., Stanislaus, S., Chen, M., Sivits, G., et al. 2009. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes, 58(1): 250–259. doi:10.2337/db08-0392. PMID:18840786.
192. Yabe, D., Komuro, R., Liang, G., Goldstein, J.L., and Brown, M.S. 2003. Liverspecific mRNA for Insig-2 down-regulated by insulin: implications for fatty acid synthesis. Proc. Natl. Acad. Sci. U.S.A. 100(6): 3155–3160. doi:10.1073/pnas.0130116100. PMID:12624180.
193. Yadav, V., Marracci, G., Lovera, J., Woodward, W., Bogardus, K., Marquardt, W., et al. 2005. Lipoic acid in multiple sclerosis: a pilot study. Mult. Scler. 11(2): 159–165. doi:10.1191/1352458505ms1143oa. PMID:15794388.
194. Yamauchi, T., Kamon, J., Minokoshi, Y., Ito, Y., Waki, H., Uchida, S., et al. 2002. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med. 8(11): 1288–1295. doi:10.1038/nm788. PMID:12368907.
195. Yang, R., Le, G., Li, A., Zheng, J., and Shi, Y. 2006. Effect of antioxidant capacity on blood lipid metabolism and lipoprotein lipase activity of rats fed a high-fat diet. Nutrition, 22(11–12): 1185–1191. doi:10.1016/j.nut.2006.08.018. PMID: 17095404.
196. Yasuno, R., and Wada, H. 2002. The biosynthetic pathway for lipoic acid is present in plastids and mitochondria in Arabidopsis thaliana. FEBS Lett. 517(1–3): 110–114. doi:10.1016/S0014-5793(02)02589-9. PMID:12062419.
197. Yaworsky, K., Somwar, R., Ramlal, T., Tritschler, H.J., and Klip, A. 2000. Engagement of the insulin-sensitive pathway in the stimulation of glucose transport by a-lipoic acid in 3T3-L1 adipocytes. Diabetologia, 43(3): 294–303. doi:10.1007/s001250050047. PMID:10768090.
198. Yi, X., Pashaj, A., Xia, M., and Moreau, R. 2013. Reversal of obesity-induced hypertriglyceridemia by (R)- a-lipoic acid in ZDF (fa/fa) rats. Biochem. Biophys. Res. Commun. 439(3): 390–395. doi:10.1016/j.bbrc.2013.08.063. PMID:23994635.
199. Zhang, L., He, H., and Balschi, J.A. 2007a. Metformin and phenformin activate AMP-activated protein kinase in the heart by increasing cytosolic AMP concentration. Am. J. Physiol. Heart Circ. Physiol. 293(1): H457–H466. doi:10.1152/ajpheart.00002.2007. PMID:17369473.
200. Zhang, W.J., Wei, H., Hagen, T., and Frei, B. 2007b. a-Lipoic acid attenuates LPS-induced inflammatory responses by activating the phosphoinositide 3-kinase/Akt signaling pathway. Proc. Natl. Acad. Sci. U.S.A. 104(10): 4077–4082. doi:10.1073/pnas.0700305104. PMID:17360480.
201. Zhang, X., Yeung, D.C., Karpisek, M., Stejskal, D., Zhou, Z.G., Liu, F., et al. 2008. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes, 57(5): 1246–1253. doi:10.2337/db07-1476. PMID:18252893.
202. Zhang, Y., Han, P., Wu, N., He, B., Lu, Y., Li, S., et al. 2011. Amelioration of lipid abnormalities by a-lipoic acid through antioxidative and anti-inflammatory effects. Obesity, 19(8): 1647–1653. doi:10.1038/oby.2011.121. PMID:21593803.
203. Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., et al. 2001. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108(8): 1167–1174. doi:10.1172/JCI13505, 10.1172/JCI200113505. PMID: 11602624.
204. Ziegler, D. 2004. Thioctic acid for patients with symptomatic diabetic polyneuropathy: a critical review. Treat. Endocrinol. 3(3): 173–189. doi:10.2165/00024677-200403030-00005. PMID:16026113.
205. Ziegler, D., Hanefeld, M., Ruhnau, K.J., Meissner, H.P., Lobisch, M., Schutte, K., and Gries, F.A. 1995. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant _-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia, 38(12): 1425–1433. PMID: 8786016.
206. Ziegler, D., Reljanovic, M., Mehnert, H., and Gries, F.A. 1999. a-Lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. Exp. Clin. Endocrinol. Diabetes, 107(7): 421–430. doi:10.1055/s-0029-1212132. PMID:10595592.
207. Ziegler, D., Ametov, A., Barinov, A., Dyck, P.J., Gurieva, I., Low, P.A., et al. 2006. Oral treatment with _-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care, 29(11): 2365–2370. doi:10.2337/dc06-1216. PMID:17065669.
208. Ziegler, D., Low, P.A., Litchy, W.J., Boulton, A.J., Vinik, A.I., Freeman, R., et al. 2011. Efficacy and safety of antioxidant treatment with a-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care, 34(9): 2054–2060. doi:10.2337/dc11-0503. PMID:21775755.
209. Zou, M.H., Kirkpatrick, S.S., Davis, B.J., Nelson, J.S., Wiles, W.G., Schlattner, U., et al. 2004. Activation of the AMP-activated protein kinase by the antidiabetic drug metformin in vivo. Role of mitochondrial reactive nitrogen species. J. Biol. Chem. 279(42): 43940–43951. doi:10.1074/jbc.M404421200. PMID:15265871.